Drug Development: From Natural Sources to FDA Approval
This paper traces the complete drug development process from initial discovery to market approval. It begins with the historical evolution of U.S. federal drug regulation, starting with the 1906 Food and Drug Act, and proceeds through the preclinical stage of compound identification, formulation, and toxicity testing. The paper then details the Investigational New Drug (IND) application process and the three formal phases of clinical investigation required by the FDA, including sample sizes, durations, and passage rates. It also addresses the role of randomized controlled trials in Phase 3 evaluation, the New Drug Application (NDA) review process, and postmarketing (Phase 4) surveillance. Throughout, the paper emphasizes the regulatory, scientific, and commercial dimensions of bringing a new pharmaceutical to market.
- Introduction to Drug Development: Overview of pharmaceutical regulation and drug sources
- History of Federal Drug Regulation in the U.S.: Evolution of U.S. drug law from 1906 onward
- The Preclinical Stage and Drug Discovery: Compound identification, formulation, and early testing
- Clinical Trial Phases 1, 2, and 3: Human subject trials, passage rates, and IND process
- Randomized Controlled Trials and Phase 3 Methodology: How randomized controlled trials assess drug efficacy
- The New Drug Application and Phase 4 Postmarketing Surveillance: NDA review process and postmarket consumer monitoring
- Conclusion: Summary of drug development necessity and complexity
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper follows a clear chronological and procedural structure, moving logically from drug discovery through each stage of clinical testing to final market approval, making it easy for readers to follow the regulatory pipeline.
- It grounds abstract regulatory concepts in specific statistics — such as passage rates (67% pass Phase 1, fewer than 50% pass Phase 2, only 5–10% reach market) — giving the argument empirical weight.
- The paper integrates historical context alongside current practice, showing how the regulatory framework evolved through specific legislation rather than treating FDA requirements as static.
Key academic technique demonstrated
The paper effectively uses process analysis as its primary organizational mode. Rather than arguing a thesis, it systematically explains a multi-step institutional procedure, citing sources at each stage to establish credibility. This technique is well-suited to technical and scientific subject matter and demonstrates how academic writing can explain complex processes clearly without sacrificing precision.
Structure breakdown
The paper opens with an overview of the pharmaceutical industry's regulatory environment, then provides historical background on U.S. drug law. It moves into the preclinical stage, followed by a detailed walkthrough of the IND application and Phases 1 through 3 of clinical trials. A dedicated section explains randomized controlled trial methodology. The paper then covers the NDA review and Phase 4 surveillance before closing with a brief conclusion that reaffirms the necessity of the process.
Introduction to Drug Development
The process of drug development is a complex one. The pharmaceutical industry is required to adhere to strict governmental regulations set out by the Food and Drug Administration (FDA), which involve numerous phases of testing and clinical trials, close monitoring of a drug's effects on users, its stability, dosage forms, and related concerns. This paper describes the drug development process as it proceeds from nature to the market.
Drugs that eventually reach the marketplace can come from a variety of sources — plants, animals, microbes, synthetic chemistry, biotechnology, and even modified molecules. Years of research and billions of dollars are invested by pharmaceutical companies as they seek out new potential drugs. All of this effort has resulted in the FDA's approval of 1,200 drugs for the marketplace since 1950 (Munos 960). The formulas that have gone into producing these drugs are diverse, with some changing over time in order to meet continually reassessed standards and updated regulations.
History of Federal Drug Regulation in the U.S.
While drugs have been produced by societies around the world throughout history, the 20th century saw the beginning of a vast federal initiative to provide oversight of the drug industry for the first time in the United States. This began with the Food and Drug Act of 1906 — the first law passed at the federal level regarding the regulation of drug standards. Various acts throughout the 20th century amended the statutes contained in this early legislation, such as the Federal Food, Drug, and Cosmetic (FD&C) Act of 1938, the Durham-Humphrey Amendment of 1952, and the Kefauver-Harris Amendments of 1962. Each of these was passed to address issues that arose in the marketplace regarding the safety of dispensation, the safety of the drugs themselves, and the authenticity of drug claims.
Today, new drugs must be sponsored in order to obtain FDA approval. Drug companies are typically the ones to sponsor new pharmaceuticals, and as sponsors they are responsible for providing evidence that the new product is safe, effective, and performs as indicated by the product description. Moreover, as a result of the development of industry regulations, drug companies must also follow protocols regarding the manufacturing, packaging, labeling, and shipping of drugs so that risks of counterfeiting and misidentification are reduced. Currently, radio-frequency identification (RFID) technology is being discussed in the industry as a means for drug manufacturers to work with regulators on maintaining high standards in shipping, tracking, and receiving (Coustasse, Kimble, Stanton, Naylor).
Works Cited
Bamelis, Lotte, Silvia Evers, Philip Spinhoven, and Arnoud Arntz. "Results of a Multicenter Randomized Controlled Trial of the Clinical Effectiveness of Schema Therapy for Personality Disorders." The American Journal of Psychiatry, vol. 171, no. 3 (March 2014): 305–322.
Coustasse A, Kimble CA, Stanton RB, Naylor M. "Could the Pharmaceutical Industry Benefit from Full-Scale Adoption of Radio-Frequency Identification (RFID) Technology with New Regulations?" Perspectives in Health Information Management (Fall 2016).
Munos, Bernard. "Lessons from 60 Years of Pharmaceutical Innovation." Nature Reviews Drug Discovery, vol. 8 (December 2009): 959–968.
Pocock, Stuart. Clinical Trials: A Practical Approach. UK: John Wiley & Sons, 2010. Print.
Shukla, Anshika, Garima Vishnoi, and Doli Rani Das. "Current Good Manufacturing Guidelines for Medicinal Product." Journal of Drug Delivery and Therapeutics, vol. 6, no. 2 (2016): 8–17.
Create your account
Always verify citation format against your institution’s current style guide requirements.